Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown(City Of Hope National Medical Center), Behnam Badie(City Of Hope National Medical Center), Todd L. Harshbarger(City Of Hope National Medical Center), Michael C. Jensen(Seattle Children's Hospital), Lihong Weng(CTI BioPharma (United Kingdom)), Anita Kurien(CTI BioPharma (United Kingdom)), Saul J. Priceman(University of Southern California), Xiuli Wang(City of Hope), Stephen J. Forman(City Of Hope National Medical Center), Massimo D’Apuzzo(City Of Hope National Medical Center), Michael E. Barish(City Of Hope National Medical Center), Mike Y. Chen(National Taiwan University), Jamie R. Wagner(City Of Hope National Medical Center), Renate Starr(City of Hope), Jana Portnow(City of Hope), Julie A. Ressler(City Of Hope National Medical Center), Jennifer Simpson(City Of Hope National Medical Center), Darya Alizadeh(CTI BioPharma (United Kingdom)), Araceli Naranjo(CTI BioPharma (United Kingdom)), Julie Kilpatrick(City Of Hope National Medical Center), M. Suzette Blanchard(City of Hope), Julie R. Ostberg(CTI BioPharma (United Kingdom))
Cited by 1,821
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754